1 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative NeoplasmsEmbolism and Thrombosis, Hemic and Lymphatic Diseases, Hemorrhage, Myeloproliferative Disorders, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, cellular phase chronic idiopathic myelofibrosis, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease, vascular disorder, venous thromboembolismRecruitingPhase 32026-03-20NCT05198960